| Market Capitalization (Millions $) |
44 |
| Shares
Outstanding (Millions) |
39 |
| Employees |
42 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-107 |
| Cash Flow (TTM) (Millions $) |
-16 |
| Capital Exp. (TTM) (Millions $) |
0 |
Rapt Therapeutics Inc
Rapt Therapeutics Inc. is a publicly traded biopharmaceutical company that focuses on developing and commercializing small molecule therapies for cancer treatment. The company was founded in 2015 and is based in San Francisco, California.
Rapt Therapeutics aims to tackle cancer through a unique approach. The company leverages the concept of immunology to develop drugs that activate T cells in the body's immune system. T cells are a type of white blood cell that can recognize and attack cancerous cells. By targeting these cells, Rapt hopes to create a new class of cancer treatments that could be used alone or in combination with existing therapies like chemotherapy or radiation.
Rapt's platform technology is based on two molecules e FLX475 and RPT193 e which are designed to target two proteins that play key roles in regulating T cell activity. These two molecules work by inhibiting a negative feedback mechanism that can suppress the immune response, allowing T cells to become more active and responsive to cancer cells. Rapt believes that its approach has the potential to improve the efficacy and durability of cancer treatments by unleashing the full potential of our body's immune system.
The company has several clinical-stage programs underway that are investigating the potential of FLX475 and RPT193 in treating a variety of cancers. Early-stage clinical trials have demonstrated promising results, paving the way for more advanced studies. Rapt Therapeutics also plans to pursue further research into its platform technology to identify and develop additional drug candidates that target other T cell-regulating proteins.
Overall, Rapt Therapeutics is a company that is focused on advanced cancer treatment through immunology. By leveraging its platform technology, the company hopes to develop innovative new therapies that can improve patient outcomes and prolong survival rates for cancer patients worldwide.
Company Address: 561 Eccles Avenue South San Francisco 94080 CA
Company Phone Number: 489-9000 Stock Exchange / Ticker: NASDAQ RAPT
|
0.000%
5.54%